A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
NCT06755944
Brain Diseases, Cardiovascular Diseases
Shijiazhuang, Hebei, China
View Trial DetailsNCT Number: NCT03507517
To reduce the incidence of stroke and standard the treatment of stroke in Liaoning Province, the present study should be conducted.
Looking for future studies?
Notify MeAll sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
The real KPI data such as intravenous thrombolysis number and quality, statin use, anti-platelet drugs, VET prevention, etc
Time frame: 2 years
The real data such as good neurological function outcome, stroke recurrence rate, death rate, etc.
Hui-Sheng Chen
Other
Quality Control Project of Secondary Prevention and Treatment of Stroke in Liaoning Province
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06755944
Brain Diseases, Cardiovascular Diseases
Shijiazhuang, Hebei, China
View Trial DetailsNCT05098236
Blindness, Brain Diseases
Rochester, New York, United States
View Trial DetailsNCT06616831
Brain Diseases, Cardiovascular Diseases
Charleston, South Carolina, United States
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details